SPARC licenses development and commercialisation rights of PDP-716 and SDN-037 to Visiox Pharma EP News Bureau Dec 8, 2021 SPARC to receive equity in Visiox along with other financial considerations
SPARC declares positive results from Phase 3 clinical trial of PDP-716 to treat open-angle glaucoma… EP News Bureau May 14, 2021 The primary endpoint of the trial was to evaluate the efficacy of once daily (QD) dosing of PDP-716 0.35 per cent compared with…
